Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Valneva (NASDAQ:VALN) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 4 | 0 | 0 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 2 | 0 | 0 | 0 | 0 |
2M Ago | 1 | 0 | 0 | 0 | 0 |
3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Valneva and provided 12-month price targets. The average target is $23.75, accompanied by a high estimate of $26.00 and a low estimate of $17.00. This upward trend is apparent, with the current average reflecting a 31.94% increase from the previous average price target of $18.00.
A clear picture of Valneva's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Evan Wang | Guggenheim | Lowers | Buy | $17.00 | $18.00 |
Edward White | HC Wainwright & Co. | Maintains | Buy | $26.00 | - |
Edward White | HC Wainwright & Co. | Maintains | Buy | $26.00 | - |
Edward White | HC Wainwright & Co. | Maintains | Buy | $26.00 | - |
Capture valuable insights into Valneva's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Valneva analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Valneva's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2023, the company experienced a revenue decline of approximately -75.7%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Valneva's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -89.9% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Valneva's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -19.66%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Valneva's ROA excels beyond industry benchmarks, reaching -6.44%. This signifies efficient management of assets and strong financial health.
Debt Management: Valneva's debt-to-equity ratio stands notably higher than the industry average, reaching 1.23. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: VALN